Lazard Asset Management
PCRX icon

Lazard Asset Management’s Pacira BioSciences PCRX Stock Holding History

Lazard Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$943K Sell
37,178
-2,292
-6% -$54.2K ﹤0.01% 1243
2026
Q1 		$892K Buy
39,470
+2,169
+6% +$48.2K ﹤0.01% 1207
2025
Q4 		$965K Sell
37,301
-4,957
-12% -$118K ﹤0.01% 1167
2025
Q3 		$1.09M Sell
42,258
-17,605
-29% -$432K ﹤0.01% 1113
2025
Q2 		$1.43M Sell
59,863
-91,165
-60% -$2.3M ﹤0.01% 1137
2025
Q1 		$3.75M Buy
151,028
+107,537
+247% +$2.57M 0.01% 769
2024
Q4 		$818K Buy
+43,491
New +$764K ﹤0.01% 1225
2023
Q4 		– Sell
-1,030
Closed -$31K – 2408
2023
Q3 		$31K Buy
+1,030
New +$37.1K ﹤0.01% 2013
2023
Q2 		– Sell
-1,544
Closed -$63K – 2477
2023
Q1 		$63K Buy
+1,544
New +$61.4K ﹤0.01% 1721
2022
Q2 		– Sell
-3,282
Closed -$250K – 2521
2022
Q1 		$250K Sell
3,282
-652
-17% -$43.5K ﹤0.01% 1217
2021
Q4 		$236K Buy
+3,934
New +$217K ﹤0.01% 1243
2020
Q3 		– Sell
-3,645
Closed -$191K – 1708
2020
Q2 		$191K Sell
3,645
-523
-13% -$21.9K ﹤0.01% 925
2020
Q1 		$139K Buy
4,168
+3,351
+410% +$139K ﹤0.01% 951
2019
Q4 		$37K Sell
817
-2,854
-78% -$121K ﹤0.01% 1117
2019
Q3 		$139K Buy
+3,671
New +$147K ﹤0.01% 957

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lazard Asset Management's PCRX Position: Q2 2026 in Review

Lazard Asset Management reduced its Pacira BioSciences (PCRX) stake by 5.8% in Q2 2026, selling an estimated $54.2K and leaving 37,178 shares worth $943K. The position accounts for ﹤0.01% of the portfolio, ranked #1243.

Lazard Asset Management first reported a position in PCRX in Q3 2019 and has held it in 15 quarters since. The position peaked at $3.75M in Q1 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Lazard Asset Management held 37,178 shares of Pacira BioSciences worth $943K as of Q2 2026.
  • Lazard Asset Management sold 2,292 Pacira BioSciences shares in Q2 2026, an estimated $54.2K.
  • Pacira BioSciences made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1243 holding.
  • Lazard Asset Management first reported a position in Pacira BioSciences in Q3 2019 and has held it in 15 quarters since.
  • Lazard Asset Management's Pacira BioSciences position peaked at $3.75M in Q1 2025.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.